Hidradenitis suppurativa is a disease involving skin folds, causing swelling of the skin and surrounding tissues, pain, and foul-smelling discharges. Effective treatment options are lacking. Recently, clinical trials conducted in our lab found Brodalumab was an effective drug for this disease. Weekly dosing achieved superior therapeutic outcomes compared to a dosing given once in every other week. Brodalumab was safe in both regimens, but blood and tissue studies to better understand this response are still needed. By performing this small pilot study and collecting blood and tissue samples from participants treated with Brodalumab once weekly we would like to better characterize the molecular response to this treatment, identify blood and tissue markers reflecting disease severity, and better understand disease mechanisms.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Enrollment
4
Subcutaneously Brodalumab/Siliq, 210mg/1.5ml once a week
The Rockefeller University
New York, New York, United States
Interleukin-17 receptor A (IL-17RA) saturation during brodalumab administration at week 12 vs baseline
Percentage change in saturation
Time frame: 12 weeks
Change in levels of IL-17A, IL-17C, IL-17, CXCL1, and CXCL8
In Brodalumab treated participants at week 12 compared with baseline
Time frame: 12 weeks
Correlate IL-17R saturation (measured by the frequencies of immune cells positive to IL-17RA by flow cytometry) with clinical measures, such as pain or the Hidradenitis Suppurativa Severity Score System (IHS4)
In Brodalumab treated participants at week 12 compared with baseline
Time frame: 12 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.